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Abstract: Influenza vaccine manufacturers require antigenically relevant vaccine viruses 
that have good manufacturing properties and are safe to use. In developing pandemic 
vaccine viruses, reverse genetics has been employed as a rational approach that can also be 
used effectively to attenuate the highly virulent H5N1 virus and at the same time place the 
H5 HA and N1 NA on a background of PR8, a virus that has been used over many decades 
to provide high yielding vaccine viruses. Reverse genetics has also been used successfully 
alongside classical reassorting techniques in the development of (swine flu) pandemic 
A(H1N1)v vaccine viruses. 
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1. Introduction 
Influenza vaccines were first developed over 60 years ago [1]. They were based upon growth of 
virus in embryonated hens’ eggs and inactivation of the virus. Little has changed over the decades in 
this respect so that even now the vast bulk of vaccine being used to combat H1N1v pandemic 
influenza is the same inactivated egg-derived vaccine. What has taken place is a fine tuning of the 
manufacturing process with the principal changes concerning the extent of purification and treatment 
of the virus antigen in order to have a less reactogenic vaccine. Nowadays most inactivated influenza 
vaccine is a detergent split or a purified subunit vaccine although some whole virion vaccine is still in 
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use [2]. This review does not address the manufacture of inactivated influenza vaccine or the many 
alternative approaches to an influenza vaccine that are being actively investigated such as live 
attenuated vaccines, recombinant vaccines, cell-derived inactivated vaccines and many other novel 
approaches. The scope of this review is to describe the development of the viruses that are required by 
the vaccine industry in order for them to manufacture an egg-derived inactivated vaccine. These are a 
crucial component of vaccine production; without a suitable virus, vaccine production would be 
severely curtailed. 
2. High Yielding/High Growth Vaccine Viruses 
Human influenza viruses do not readily grow in embryonated hens’ eggs; they have to adapt to this 
method of propagation [3–5]. This was first realised during the 1940s and, once adaptation has 
occurred, it is a highly efficient method of preparing large quantities of influenza virus [1]. The work 
of E.D. Kilbourne in the 1960s was very important for influenza vaccine production [6,7]. He 
demonstrated that by infecting an egg with two separate viruses, one a high yielding strain in eggs 
such as the well used PR8 virus and the other a wild type virus of low egg passage, a progeny virus 
could be selected from the mixed population of recombinants with the high yielding phenotype of PR8 
and the surface antigens of the wild type virus (Figure 1). Selection for viruses with the wild type 
surface antigens was achieved using anti-PR8 antiserum and selection for high growth was achieved 
by passage at limit dilution. The intent was that such recombinant viruses would be useful for the 
efficient manufacture of influenza vaccine. This indeed was the case and vaccine derived from a 
genetically recombined virus was shown to have the appropriate immunogenicity in humans [8]. 
Figure 1. Diagrammatic representation of the classical reassortment of influenza viruses. 
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This process has been used to this day in deriving vaccine viruses and is undertaken by a small 
network of laboratories working under the umbrella of the World Health Organisation (WHO) 
whenever a new influenza A strain is recommended for inclusion in vaccine. Whilst it was suspected Viruses 2010, 2                  
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early on that the genome of influenza viruses was not a single nucleic acid molecule, it was some time 
after the demonstration that influenza viruses will readily recombine that it was definitively shown that 
the genome consists of eight specific segments of RNA; thus this high level of recombination was in 
fact due to ‘reassorting’ of the genome segments during a co-infection [6,9,10]. The high yielding 
recombinants (now known as reassortants) first described by Kilbourne typically (but not always) have 
six segments derived from PR8 (generally termed the internal genes) and two segments encoding the 
surface HA and NA antigens from the wild type virus; these are termed 6:2 reassortants. Studies have 
shown that at minimum, high growth reassortants (HGR) based upon PR8 had the PR8 segment 
encoding the matrix protein [11]. Whilst this process of deriving an HGR remains an essential element 
of influenza vaccine production, it is highly serendipitous and successful derivation of a useful HGR 
within the short time frame of the annual influenza vaccine manufacturing season is not guaranteed. 
3. Reverse Genetics 
In more recent years, technology known as reverse genetics has allowed a rational approach to the 
development of a candidate vaccine virus [12–14]. Reverse genetics involves cloning the individual 
RNA genome segments of the virus into bacterial plasmids under the control of a mammalian DNA 
dependent RNA polymerase I (polI)-dependent promoter. Expression of these plasmids in an 
appropriate mammalian cell line generates exact copies of the viral genome segments. With the 
cotransfection of the cells with plasmids that express the replicase activity of the virus (PA, PB1, PB2 
and NP), infectious virus can be reconstituted (or rescued) (Figure 2). 
Figure 2. Diagrammatic representation of the reverse genetics process in generating a 6:2 
reassortant virus containing the six internal genome segments from PR8 and two genome 
segments (the HA and NA encoding segments) from a wild type virus. 
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The way in which this technology can be used to generate potential high growth reassortants is that 
a virus can be reconstituted specifically with the six internal genome segments of PR8, the high 
yielding strain, and the two genome segments encoding the HA and NA surface antigens of a wild type 
virus to create a specific 6:2 reassortant. This is the gene constellation of many classically derived 
HGRs and studies show that reverse genetics derived 6:2 viruses have growth characteristics 
comparable to classically derived reassortants [15]. From a practical point of view, the six internal PR8 
gene segments can be prepared in advance and used as and when required; similarly for the four 
plasmids expressing the helper replicase function. Only the two surface antigen segments from the new 
wild type strain need be cloned at the point of time when a new vaccine strain is required. Other 
investigators have designed rescue systems based upon eight plasmids and some on even fewer 
plasmids or other vectors, but essentially they all operate on the same principle of expressing   
intra-cellular full length copies of the required eight viral genome segments and helper replicase   
function [16–18]. Thus reverse genetics can be used for the rational design of a reassortant influenza 
vaccine virus. 
There are two additional advantages of this approach. Firstly, clinical samples from patients 
infected with influenza may contain other viruses with which a patient is co-infected which might 
replicate in eggs alongside the wild type influenza virus and remain during the derivation of an HGR 
by the classical approach. Extracting and cloning the RNA segments of an influenza virus during the 
reverse genetics approach eliminates this risk due to the processes involved and the specificity of PCR 
used during cloning. Furthermore, for a reverse genetics derived vaccine virus, the HA and NA 
segments could derive from a wild type virus isolated in cell cultures that have not been validated to be 
free of endogenous viral contamination; again, the reverse genetics process would eliminate any such 
infectious material. The second advantage is that when the viral genome is being cloned, the genetic 
sequences can be modified in a rational manner to introduce advantageous features into the virus that 
is being rescued. This feature came to the fore when the threat of a pandemic due to H5N1 avian 
influenza appeared on the horizon in early 2004. 
4. Use of Reverse Genetics to Derive Safe H5N1 Candidate Vaccine Viruses 
Due to the highly pathogenic features of the avian H5N1 virus, it was not practical from a safety 
point of view to use the wild type virus in an egg production environment. Further, although the virus 
itself did not have to undergo an egg-adaptation step, being of avian origin in the first place, achieving 
optimal growth was technically demanding because the virus was highly virulent within the 
embryonated egg which caused considerable tissue destruction and subsequently it was difficult to 
purify virus from the fluids. The major molecular basis for the highly pathogenic phenotype resides 
within the HA genome segment and so reassorting by classical techniques would not necessarily have 
resulted in a safe virus, even though the intention would have been to introduce as many PR8 
backbone segments into a reassortant virus as could be achieved. Thus it was by using reverse genetics 
that a safe and useful 6:2 reassortant virus could be created.  
The molecular feature of high pathogenicity is a short stretch of basic amino acids located within 
the HA structure at a point known as the cleavage site (the HA has to be cleaved by a proteolyic 
enzyme in order for the virus to be infectious) [19,20]. The vast majority of influenza virus strains are Viruses 2010, 2                  
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of low pathogenicity and contain a single arginine residue at the cleavage site. These HAs are cleaved 
by a trypsin-like protease found generally at epithelial cell surfaces which contributes to the tropism of 
the virus [21]. In highly pathogenic strains (limited to haemagglutinins of the H5 and H7 subtypes) an 
extra 3–5 basic (arg or lys) amino acids have been inserted (purportedly by polymerase stuttering 
during replication of the genome segment). The presence of these extra amino acids allows ubiquitous 
intracellular subtilisin-like proteases to cleave the HA and results in an altered tropism of the virus 
such that it can cause a systemic and highly pathogenic infection [21]. During cloning of the HA from 
a highly pathogenic H5 or H7 virus, it is technically straightforward to remove the region of nucleic 
acid encoding these amino acid residues and return the HA to a non-pathogenic phenotype [22]. 
At the onset of the avian H5N1 pandemic threat, there was a call from WHO to the small network 
of laboratories with this technology to develop appropriate high yielding and safe candidate vaccine 
viruses. This was achieved rapidly by three laboratories including ours in which the vaccine virus 
NIBRG-14 was generated within three weeks [15,23]. NIBRG-14 contains the six internal genome 
segments from PR8 and the HA and NA genome segments from a human H5N1 isolate, 
A/Vietnam/1194/2004. However, these H5N1 candidate viruses could not be distributed to the vaccine 
manufacturing industry until it had been demonstrated that they were indeed no longer highly 
pathogenic. This was achieved by a number of assays [15]. Firstly, sequencing was used to 
demonstrate that the HA genome segment of NIBRG-14 had the deletion it was designed to have. 
Secondly, growth of influenza viruses in cell culture typically requires the addition of trypsin to cleave 
the HA to form infectious particles. In the case of the highly pathogenic influenza viruses, there is no 
requirement for trypsin because endogenous proteases in the cell cultures will perform this action. 
Thus the highly pathogenic phenotype can be assayed for by assessing the ability of a virus to form 
infectious centres in the presence or in the absence of added trypsin. A virus of the non-pathogenic 
phenotype will form infectious centres only in the presence of trypsin. This was found to be the case 
for NIBRG-14 confirming the non-pathogenic nature of the virus. Three in vivo assays were also 
utilised. The wild type H5N1 viruses cause embryo death after inoculation of hens’ eggs. The 6:2 
reassortant NIBRG-14 did not cause embryonic death indicating that the virus was attenuated 
compared to the wild type. In international veterinary surveillance of avian viruses, the in vivo chicken 
pathogenicity (IVCP) test is a well established assay stipulated by the Office International des 
Epizooties to determine the level of pathogenicity of H5 and H7 isolates [24]. The most pathogenic H5 
and H7 viruses score a maximum of 3.0 in the IVCP assay whilst a value of <1.2 is indicative of a 
virus of low pathogenicity. NIBRG-14 scored 0.0 in this assay confirming again the highly attenuated 
nature of the virus. 
Because of the novelty of this situation, however, there remained concern regarding the 
pathogenicity of such viruses for mammalian species. The ferret is the mammalian model of choice for 
in vivo studies of influenza viruses and a ferret assay was adopted by the WHO as the standard test to 
be used in assessing the mammalian pathogenicity of candidate vaccine viruses that have been derived 
from pathogenic wild type viruses [25]. NIBRG-14 was inoculated intranasally into four ferrets 
alongside the wild type virus and PR8 which is highly attenuated for humans. In this assay, the 
pathogenicity of NIBRG-14 as determined by virus production in the respiratory tract and in specified 
organs, and by histological examination, was similar to the highly attenuated PR8 and considerably 
less than that of its wild type parental H5N1 virus (A/Vietnam/1194/2004) which was highly Viruses 2010, 2                  
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pathogenic and caused systemic infection. Consequently NIBRG-14 was deemed safe and suitable for 
pandemic influenza vaccine manufacture. Many influenza vaccine manufacturers have used NIBRG-14 
to prepare pandemic-like vaccines for investigative purposes and in Europe some have used such studies 
with NIBRG-14 to gain regulatory approval of an H5N1 vaccine as part of the ‘core’ dossier regulatory 
approach developed by the EMEA as a fast track procedure for pandemic vaccine approval [26–30].  
Since 2004, H5N1 has remained a major pandemic threat. As is typical for influenza viruses, as the 
H5N1 panzootic developed the viruses have undergone genetic and antigenic drift and many clades 
and sub-clades which are antigenically distinct have been identified [31]. The network of WHO 
laboratories able to use reverse genetics to create candidate vaccine viruses has continued to respond 
to the emergence of new H5N1 variants and since the start of the panzootic at least 17 candidate 
vaccine viruses have been developed, all by reverse genetics technology (Table 1)[31]. Vaccine 
manufacture also requires virus-specific reagents to measure and standardise the antigen content of 
vaccine [32]. These reagents consist of a vaccine virus-specific antigen of calibrated content and an 
appropriate anti-antigen antiserum. These reagents are used commonly in the single radial 
immunodiffusion (SRD) assay for quantification of HA antigen in vaccine or at different stages of the 
manufacturing process. Such reagents have also been created for many of the candidate H5N1 vaccine 
viruses and many are available from NIBSC [33]. 
Table 1. Available H5N1 vaccine viruses (as of September 2009) 
1. 
Clade  Strain  Institution 
2 
1 
A/Vietnam/1203/2004 
A/Vietnam/1194/2004 
A/Cambodia/R0405050/2007 
CDC; SJ/HKU/NIAID  
NIBSC 
NIBSC 
2.1 
A/Indonesia/5/2005 
A/duck/Hunan/795/2002 
CDC 
SJ/HKU/NIAID 
2.2 
A/bar-headed goose/Qinghai/1A/2005 
A/whooper swan/Mongolia/244/2005 
A/chicken/India/NIV33487/2006 
A/Egypt/3300-NAMURU3/2008  
SJ/HKU/NIAID 
SJ/NIAID 
CDC/NIV 
CDC 
2.2.1 
A/turkey/Turkey/1/2005 
A/Egypt/2321/2007 
NIBSC 
CDC 
2.3.2  A/common magpie/Hong Kong/5052/2007 SJ/HKU/NIAID 
2.3.4 
A/Anhui/1/2005 
A/Japanese white-eye/Hong Kong/1038/2006 
A/duck/Laos/3295/2006 
CDC 
SJ/HKU/NIAID 
FDA 
4  A/goose/Guiyang/337/2006 SJ/HKU/NIAID 
7  A/chicken/Vietnam/NCVD-03/2008-like CDC 
1 Reproduced with permission from reference [31] (World Health Organization). 
2 CDC–Centers for Disease Control and Prevention, USA; FDA–Food and Drug Administration, 
USA; NIAID–National Institute of Allergy and Infectious Disease, NIH, USA; NIBSC–National 
Institute for Biological Standards and Control, UK; NIV–National Institute of Virology, India; 
SJ–St Jude Children’s Research Hospital, USA; HKU–University of Hong Kong, China Hong 
Kong SAR. Viruses 2010, 2                  
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When the NIBRG-14 virus began to be used in vaccine manufacture, the vaccine industry noted that 
this and other H5N1 strains gave suboptimal yields of antigen. This caused concern in that the 
projected supply of vaccine in the event of a pandemic was going to be considerably less than 
previously estimated. At NIBSC, investigations were undertaken to determine the nature of the 
reduced antigen yield. Virus growth did not seem to be compromised as the virus could be grown to a 
reasonable titre in eggs; however, in the process of calibrating the reagents for vaccine potency, it was 
noticed that the HA content of harvested virions appeared to be less than normal. HA content of a virus 
preparation is typically determined from a PAGE analysis of the virus run under non-reducing or 
reducing conditions, followed by densitometric evaluation of the percentage HA of total virion protein. 
For the H5N1 viruses and vaccine viruses containing the H5N1 surface antigens, there were technical 
problems with PAGE analysis. Under non-reducing conditions, high molecular weight aggregates of 
protein were observed which contained HA, making assessment of the principal HA band unreliable, 
whilst under reducing conditions, the HA1 moiety ran adjacent to the NP protein and the HA2 moiety 
ran adjacent to the M1 protein, again making densitometric measurements potentially unreliable. This 
problem was overcome by the use of an endoglycosidase digestion step to remove the carbohydrate 
moieties from the HA glycoprotein [34]. This had two effects, firstly it caused the HA1 and the HA2 to 
run as tighter bands in reduced PAGE and secondly it reduced the molecular weight of these proteins 
so that they migrated faster into a region of the gel clear of other viral proteins and thus densitometric 
analysis could be applied with greater reliance on the quantitative measurement. Analysis of NIBRG-
14 in this way confirmed that the HA content was only 78% that of virus PR8 and would contribute to 
the low yield of antigen being derived from this and other H5N1 vaccine candidate viruses [34].  
Studies are underway at NIBSC to improve the HA content of NIBRG-14 virions and will be the 
subject of a separate publication. Other laboratories have reported on approaches to improve pandemic 
candidate vaccine viruses, for example, by use of alternate PR8 backbone strains, by creating 7:1 
reassortants in which only the HA is derived from the wild type virus, or by genetic modification of 
the neuraminidase [35,36]. 
5. Library of Viruses of Pandemic Potential 
Highly pathogenic avian H5N1 viruses are not the only pandemic threat, as other animal viruses 
have occasionally infected humans and other mammals causing disease ranging from mild symptoms 
to fatal outcome [37–39]. While none of these viruses has yet been shown to transmit efficiently from 
human to human, it is difficult to determine the degree of pandemic risk posed by animal influenza 
viruses of various subtypes. Therefore, pandemic preparedness should be extended to viruses beyond 
the highly pathogenic H5N1 viruses. This could include the generation of candidate vaccine viruses 
from viruses that are considered to be of pandemic concern before they emerge as novel human 
pathogens, i.e. in the pre-pandemic period. Consequently, and due to the large number of potential 
viruses that could be subsumed under this category, a ‘library’ of candidate vaccine viruses can be 
envisaged as one component in the global pandemic preparedness tool kit. This library is made up of 
viruses representing various subtypes and will hopefully cover most animal influenza viruses that may 
cross into the human population and threaten the advent of a new influenza pandemic. If a virus of a 
subtype represented within such a library were to cause human infections and spread between humans Viruses 2010, 2                  
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in the future, vaccine production could be initiated almost immediately based upon a candidate vaccine 
virus from the library, saving time on the path towards a pandemic vaccine. This first vaccine would 
not be perfectly matched to the actual outbreak virus, but might provide protection from infection 
and/or (severe) disease if the candidate vaccine virus and the virus of concern were antigenically 
related to such a degree that a protective immune response against the latter can be elicited by   
the former. 
In contrast to highly pathogenic H5N1 viruses, for which information about their geographical 
distribution, evolution and their epidemiological characteristics is actively sought and usually 
accessible, less information is available for avian and other animal viruses of other subtypes. In 
addition, the number of viruses of pandemic concern is potentially large, depending on the criteria 
applied to the designation of viruses as relevant in pandemic preparedness activities. Therefore, viruses 
to be included in a library programme have to be carefully selected to ensure (i) only a manageable, 
limited number of candidate vaccine viruses have to be generated and (ii) these are as representative, 
antigenically and genetically, of animal viruses of pandemic potential as possible. The main selection 
criterion for inclusion in a library of strains should be antigenic representativeness, i.e. the chosen 
virus should induce antibodies that cross-react with as many viruses of a given subtype as possible. 
While this is hard to predict, antigenic characterisation of viruses by haemagglutination inhibition 
assay using post-infection ferret sera raised against a number of viruses from the same subtype usually 
gives an indication of where within the antigenic spectrum of a subtype any new virus is situated, and 
thus of how representative of other viruses it is. If done at larger scale, this analysis can be aided by 
antigenic cartography [40]. Unfortunately, for some subtypes of interest, very little antigenic 
information is available in the public domain; similarly, reagents, in particular ferret antisera, are not 
widely available for some subtypes. Therefore, in the absence of antigenic data, phylogenetic data 
describing the evolutionary relatedness of viruses may serve as a substitute in choosing a virus for 
inclusion in a library. 
There are a number of possibilities for the type of candidate vaccine virus included in a library of 
strains. As most avian (and other animal) influenza A viruses, apart from some H5 and H7 viruses, are 
of low pathogenicity, classical reassortment with PR8 can be applied to generate a candidate vaccine 
virus. Reverse genetics technology can equally be used, and will normally result in viruses that are 
genetically and antigenically identical to those that can be generated by classical reassortment because 
the HA gene does not need to be modified in the case of low-pathogenic wild type viruses. In addition, 
wild-type viruses themselves may be used as candidate vaccine viruses in the case of low-pathogenic 
viruses; many viruses of pandemic concern are avian in origin, and some of these grow to high titres in 
embryonated hens’ eggs without further adaptation, obviating the need to manipulate the virus in order 
to improve growth properties [41]. 
We and others have started to develop such libraries of candidate vaccine viruses representing 
mainly avian viruses of a number of subtypes [42,43]. Table 2 shows the library of viruses available 
from NIBSC; viruses representing HA subtypes H5, H7, H9 and H2 are included in the library, with 
most candidate vaccine viruses having been derived using reverse genetics technology. These subtypes 
were chosen as they have all been responsible for infection and disease in humans and thus can be 
considered of higher pandemic risk as compared to avian viruses not known to have infected humans. 
The full potential of the library in relation to shortening the time between the recognition of a new Viruses 2010, 2                  
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virus in humans and a vaccine offering protection from this virus can only be realised if vaccine 
manufacturers obtain the candidate vaccine viruses during the pre-pandemic period and develop their 
master and working seeds ahead of a pandemic emerging; thus, vaccine production could be initiated 
from stored seeds whenever the need for a new vaccine is recognised or announced. Ideally, 
manufacturers would even produce trial lots of vaccine from (some) library viruses in order to gain 
experience with a new subtype. While this may appear wasteful at first glance, production of vaccine 
for H5N1 has shown that new subtypes can present new challenges during manufacture. Problems 
such as the low yield observed for some H5N1 candidate vaccine viruses might be revealed by pilot 
scale manufacturing. If results from this work are shared with the influenza vaccine production 
community as well as the laboratories generating candidate vaccine viruses, an iterative cycle of 
improvement of candidate vaccine viruses may be initiated, resulting in better candidate vaccine 
viruses and, ultimately, better pandemic preparedness for the world. 
Table 2. NIBSC library of pandemic vaccine viruses. 
Subtype   Wild-type virus  Candidate vaccine virus 
H5N3   A/duck/Singapore-Q/F119-3/1997   ARIV-1
1
 
H5N1 (clade 1)   A/Hong Kong/213/2003   NIBRG-12 
2
 
H5N1 (clade 1)   A/Vietnam/1194/2004   NIBRG-14 
H5N1 (clade 1)   A/Cambodia/R0405050/2007   NIBRG-88 
H5N1 (clade 2.2.1)   A/turkey/Turkey/1/2005   NIBRG-23 
H7N1  A/turkey/Italy/3889/1999 (low path)  wt 
H7N3   A/mallard/Netherlands/12/2000   NIBRG-60 
H7N1   A/mallard/Netherlands/12/2000   NIBRG-63 
H7N2   A/New York/107/2003   NIBRG-109 
H9N2   A/Hong Kong/1073/1999 (G1 lineage)   wt 
H9N2   A/chicken/Hong Kong/G9/1997(G9 lineage)   NIBRG-91 
H2N3   A/mallard/England/727/2006   NIBRG-107 
1 A classically derived reassortant. 
2 All vaccine viruses coded ‘NIBRG’ are reverse genetics derived. 
6. Pandemic A(H1N1)v Vaccine Development 
At the end of April 2009, the system of creating vaccine viruses using reverse genetics was put to 
the test with the appearance of so-called swine flu in persons in Mexico and bordering states of the 
USA. The causative agent, an influenza H1N1 virus, was antigenically distinct from the H1N1 strains 
currently circulating in the human population. The WHO network of laboratories, without any need to 
be requested to do so, immediately began the reverse genetics process for the derivation of a 6:2 safe 
reassortant vaccine virus. Unfortunately, no H1N1 virus had yet been incorporated into the library of 
viruses of pandemic potential described above. However, the experience gleaned over the past few 
years on H5N1 vaccine development was of immense value and by late May 2009, candidate reverse 
genetics-derived vaccine viruses were available from two laboratories, CDC (USA) and NIBSC   
(UK) [44,45]. Viruses 2010, 2                  
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There were major differences in deriving a vaccine virus from pandemic H1N1v compared to H5N1 
viruses. Firstly, in the case of H1N1v, the virus clearly was able to infect humans quite readily and was 
not adapted to growth in eggs. Secondly, the virus was not a highly pathogenic virus in the way that 
the current H5N1 viruses are. The HA of H1N1v does not have any extra basic amino acid residues at 
the HA cleavage site and so there was no requirement to delete a portion of the HA genome segment–
the viral RNA could be cloned into a rescue plasmid directly with no modification. Furthermore, 
although the virus would need to be handled under BSL3 containment, it was nowhere as virulent as 
the avian H5N1 viruses, and finally, the absence of the highly pathogenic motif in the HA meant that 
high yielding reassortant viruses could be derived by classical reassorting as well as by reverse 
genetics. Consequently, in the early stages of the epidemic both reverse genetics and the classical 
reassorting processes were used in parallel amongst the laboratories involved, with X-179A being 
developed at the New York Medical College and IVR-153 at CSL, Australia [46,47]. Indeed, of the 
initial candidate vaccine viruses created, the most favoured was the classical reassortant X-179A. X-
179A contained five genome segments from PR8 and three from the wild type A/California/07/2009 
and was preferable in terms of viral protein yield to two  other candidates (5.9 vs. 3.4-3.6 mg 
protein/100 eggs [unpublished observation]), including the one developed at NIBSC, NIBRG-121. All 
of the above was achieved during May 2009 prior to the WHO declaring level 6 pandemic influenza, 
which occurred on June 11, 2009. 
During the development of the first vaccine viruses, following from an expert discussion, the WHO 
advised that vaccine production using an attenuated H1N1v vaccine virus could proceed at a BSL 2 
enhanced containment level [48]. Whilst it was felt probable that a 6:2 reassortant (or in the case of X-
179A, a 5:3 reassortant) between PR8 and the parental wild type virus A/California/07/2009 would be 
attenuated in comparison to the wild type virus, it was incumbent upon the scientists responsible to 
assess the virulence of H1N1v vaccine viruses empirically. Consequently, the ferret pathogenicity test 
as developed for H5N1 vaccine viruses was applied to the above three newly derived H1N1v candidate 
vaccine viruses and showed the viruses, both classical and reverse genetics derived, to be attenuated in 
comparison with wild type H1N1v [49]. This was still problematic for industry and it was not until the 
pandemic had spread sufficiently, to the extent that it was clearly circulating in the locality of vaccine 
manufacture plants, that the WHO lowered the level of containment to BSL 2, which is the level at 
which the vaccine industry manufactures seasonal flu vaccine and under which they can operate to 
high efficiency [50]. 
These first vaccine candidates were useful but produced only about one half the amount of antigen 
typically obtained for a seasonal H1N1 virus. In this case, unlike with the H5N1 vaccine viruses, the 
reason was virus growth and not HA content per virion. Thus work continued during the summer of 
2009 to develop improved vaccine viruses. By August good progress had been made. Here at NIBSC, 
continued passage of NIBRG-121 in embryonated eggs resulted in a virus (NIBRG-121xp) that 
produced approximately twice as much viral protein and similar to the amount achieved with seasonal 
H1N1 vaccine viruses. At the same time the NYMC laboratory, by further reassortment of X-179A, 
produced a new reassortant (X-181) which produced viral protein to similar levels as NIBRG-121xp. 
These two vaccine viruses are now being used by various manufacturers to produce pandemic 
A(H1N1)v influenza vaccine. Table 3 lists available candidate vaccine viruses for development of 
pandemic H1N1v vaccines [51]. Viruses 2010, 2                  
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Table 3. Available pandemic H1N1v 2009 vaccine viruses (as of October 2009) 
1. 
Parent virus  Vaccine virus  Developing institute
2  Available since 
A/California/07/2009  Wild type  CDC  May 09 
 X-179A 
cl  NYMC  27 May 09 
 IVR-153
cl  CSL  04 June 09 
 X-181
 cl  NYMC  14 Sept 09 
 X-181A
cl  NYMC  14 Sept 09 
 NIBRG-121
rg  NIBSC  27 May 09 
 NIBRG-121xp
rg  NIBSC  06 Aug 09 
A/California/04/2009  Wild type  CDC  May 09 
 CBER-RG2
rg  CBER  19 June 09 
A/Texas/5/2009  Wild type  CDC  May 09 
 IDCDC-RG15
rg  CDC  27 May 09 
 IDCDC-RG20
rg  CDC  22 July 09 
A/England/195/2009  Wild type  NIBSC  May 09 
 NIBRG-122
rg  NIBSC  22 July 09 
A/Texas/5/2009 & 
A/New York/18/2009 
IDCDC-RG18
 rg  CDC  22 July 09 
A/New York/18/2009  IDCDC-RG22
rg  CDC  22 July 09 
1  Reproduced with permission from reference [51] (World Health Organization). 
2  CBER–Centers for Biologics Evaluation and Research, USA; CDC–Centers for Disease 
Control and Prevention, USA; CSL–Commonwealth Serum Laboratories, Australia; 
NYMC–New York Medical College, USA; NIBSC–National Institute for Biological 
Standards and Control, UK. 
cl classical reassortant 
rg reverse genetics derived 
Each of the H1N1 vaccine viruses created during the summer of 2009 contained at least one 
mutation in the HA compared to wild type virus isolated in cell culture. These were most likely due to 
the need to egg-adapt the wild type H1N1v virus isolates and many of the mutations detected were 
similar to what has been observed in the past for the egg-adaptation of seasonal H1N1 wild type 
viruses [5]. Interestingly, NIBRG-121xp and X-181 had additional mutations, compared to NIBRG-121 
and X-179A respectively, reflecting presumably a further adaptation of these viruses to growth in 
hens’ eggs. Fortunately, none of the HA mutations observed altered the antigenicity of the viruses and 
they remained suitable A/California/07/2009-like vaccine viruses. 
To date, the H1N1v viruses have remained antigenically stable. However, these are influenza 
viruses and inevitably they will undergo antigenic drift and new vaccine viruses will be required to 
reflect these changes. In the past, the antigenic drift of human influenza A viruses has occurred in a 
linear fashion and as one variant gradually replaces a previous one, the strain that is most likely to 
dominate and cause disease has been recommended for inclusion in vaccine. In contrast, the drift of 
H5N1 viruses within avian species has not occurred in a linear fashion and many different antigenic 
variants co-exist in both the same and in disparate geographical regions. With good fortune, the 
H1N1v viruses will follow a linear evolution. Viruses 2010, 2                  
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